MedTrace Logo

Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome

NCT00157274 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2007-04-03

No results posted yet for this study

Summary

The investigators designed a compassionate basis phase II study for refractory/relapsed mycosis fungoides/Sezary syndrome consisting of alemtuzumab (Campath) for primary evaluation of overall response and time to relapse. Other goals to consider are toxicity and time to new therapy.

Conditions

  • Mycosis Fungoides
  • Sezary Syndrome

Interventions

DRUG

alemtuzumab

Sponsors & Collaborators

  • Latin American Cooperative Onco-Haematology Group - Peru

    lead OTHER

Principal Investigators

  • Brady E Beltran, MD · LACOGH - PERU

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Completion
2008-07-31

Countries

  • Peru

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00157274 on ClinicalTrials.gov